 Cue Biopharma is a clinical-stage biopharmaceutical company developing novel injectables that modulate targeted T-cells. Cue Biopharma has expanded its pipeline to include 7 therapeutics with 1 undergoing clinical trials CUE-101. CUE-101 is Cues lead therapeutic halfway through Phase 1 and targeting HPV-related cancers. 